Chronic Kidney Disease Global Market Report 2024

The chronic kidney disease market size has grown strongly in recent years. It will grow from $65.74 billion in 2023 to $70.2 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth observed in the historical period can be attributed to several factors, including the prevalence of the hypertension and diabetes epidemic, an aging population, unhealthy lifestyles, disparities in healthcare access, and advancements in medical technologies. These factors collectively contributed to the increased incidence and awareness of chronic kidney disease during that period.

The chronic kidney disease market size is expected to see strong growth in the next few years. It will grow to $88.26 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The anticipated growth in the forecast period can be attributed to a focused healthcare policy, the development of precision medicine, an increase in obesity rates, the growth of chronic diseases, and improvements in healthcare access. Key trends in the forecast period include campaigns promoting early screening, the integration of telemedicine and remote monitoring, programs empowering patients, initiatives for community-based care, and the integration of nutritional therapy. These trends collectively contribute to the evolving landscape of chronic kidney disease management and care.

The escalating prevalence of kidney disease is poised to drive the expansion of the chronic kidney disease (CKD) market. Kidney diseases encompass various conditions that affect the kidneys' function and structure, often necessitating medication to manage symptoms, control blood pressure, and minimize protein loss. As per data from the Centers for Disease Control and Prevention in July 2022, approximately 15% or 37 million individuals in the US grapple with kidney disease, underscoring the surge in its prevalence. Consequently, this mounting prevalence is a key driver propelling the growth trajectory of the chronic kidney disease market.

The burgeoning aging population is anticipated to contribute significantly to the chronic kidney disease market's expansion. The term 'aging population' denotes a demographic trend marked by a higher proportion of elderly individuals within a society or populace. This demographic shift is closely associated with an elevated reliance on chronic kidney disease (CKD) management due to the rising incidence of kidney-related issues among the elderly. With age, the risk of kidney ailments, including CKD, tends to escalate. Notably, the World Health Organization's October 2022 report highlights a rapid growth projection for the global population aged 60 years and older, expected to double by 2050, reaching an estimated 2.1 billion individuals. Hence, the increasing aging demographic is a significant factor propelling the chronic kidney disease market's growth trajectory.

Product innovation stands out as a pivotal trend gaining momentum in the chronic kidney disease market. Companies navigating this sector are dedicating efforts toward developing innovative products to fortify their market presence. For example, Bayer, a Germany-based biotechnology and pharmaceutical entity, unveiled Kerendia (finerenone) in August 2022. This groundbreaking medicine, categorized as a non-steroidal, selective mineralocorticoid receptor antagonist, offers a novel approach to decelerate chronic kidney disease progression among diabetic patients. Its distinctive mechanism involves the blocking of mineralocorticoid receptor (MR) overactivation, thereby addressing factors contributing to CKD progression and associated cardiovascular damage, setting it apart from existing treatments.

Major players in the chronic kidney disease market are engaging in strategic partnerships to explore the safety and efficacy of an enhanced Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device. These strategic partnerships involve collaborations where companies harness each other's strengths and resources to achieve mutual benefits. As an illustration, in June 2023, AWAK Technologies Pte Ltd., a Singapore-based medical technology firm, forged a partnership with Singapore General Hospital Pte Ltd. (SGH), an academic health science center and hospital entity in Singapore. This collaboration aims to revolutionize kidney disease diagnosis, treatment, and management by spearheading the development and evaluation of AWAK PD, a wearable and ultra-portable peritoneal dialysis (PD) system. This innovative system allows end-stage kidney disease patients the flexibility to undergo dialysis at home and while on the move, thereby enhancing their quality of life and treatment convenience.

In January 2023, the US-based biopharmaceutical company AstraZeneca Pharmaceuticals LP successfully acquired CinCor Pharma Inc. for $1.8 billion. Through this acquisition, AstraZeneca aims to enrich its cardiorenal pipeline by incorporating CinCor's candidate medicine, baxdrostat (CIN-107). Baxdrostat is an aldosterone synthase inhibitor (ASI) designed for blood pressure control in the treatment of resistant hypertension. CinCor Pharma Inc., based in the US, is a clinical-stage biopharmaceutical company specializing in the development of products for the treatment of resistant and uncontrolled hypertension, as well as chronic kidney disease.


Major companies operating in the chronic kidney disease market report are Pfizer Inc., Johnson and Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott laboratories Inc., GlaxoSmithKline PLC, Takeda Pharmaceuticals Ltd., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Novo Nordisk AS, Siemens Healthineers AG, AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Beckman Coulter Inc., Kissei Pharmaceutical Co. Ltd., Akebia Therapeutics Inc., Mission Therapeutics Ltd., Tricida Inc., Regulus Therapeutics Inc., Goldfinch Bio Co, Alio Inc., Monogram Health, Strive Health, Maze Therapeutics, ProKidney Corp.

North America was the largest region in the chronic kidney disease market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Key diagnostic tests for chronic kidney disease include blood tests, urine tests, imaging tests, and kidney biopsy. Blood tests involve the examination of a blood sample for medical evaluation. Treatment modalities encompass drugs, dialysis, kidney transplants, ACE inhibitors, and other interventions. These drugs can be administered through oral, intravenous, and subcutaneous routes, catering to various end-users such as hospitals, clinics, ambulatory surgery centers (ASCS), dialysis centers, and others.

The chronic kidney disease market research report is one of a series of new reports that provides chronic kidney disease market statistics, including the chronic kidney disease industry global market size, regional shares, competitors with a chronic kidney disease market share, detailed chronic kidney disease market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic kidney disease industry. This chronic kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic kidney disease market consists of revenues earned by entities by providing peritoneal dialysis, in-center hemodialysis, and home hemodialysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic kidney disease market also includes sales such as captopril, enalapril, finerenone, and fosinopril used during the treatment procedure. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.